8 results on '"Gloger, S."'
Search Results
2. Die bronchogene Zyste: ein Fallbericht zur Darstellung als Differentialdiagnose der retroperitonealen Raumforderung und Nebennierenneoplasie
- Author
-
Gloger, S
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Einleitung: Die bronchogene Zyste ist eine gutartige Raumforderung, die vorwiegend thorakal als embryonale Fehlbildung entsteht, jedoch in seltenen Fällen retroperitoneal vorkommt und hier vorwiegend differentialdiagnostisch zu neoplastischen Prozessen der Nebennieren berücksichtigt werden[zum vollständigen Text gelangen Sie über die oben angegebene URL], 66. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie
- Published
- 2020
- Full Text
- View/download PDF
3. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- Author
-
Paul, O'Connor, Wolinsky, Jerry S., Christian, Confavreux, Giancarlo, Comi, Ludwig, Kappos, Olsson, Tomas P., Hadj, Benzerdjeb, Philippe, Truffinet, Lin, Wang, Aaron, Miller, Temso Trial Group Reingold, Freedman Ms S., Cutter, G., Antel, J., Barkhof, F., Maddrey, W., Ravnborg, M., Schenker, S., O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Miller, A., Freedman, Mark S., Narayana, P. A., Nelson, F., Vainrub, I., Datta, S., He, R., Gates, B., Ton, K., Wamil, B., Truffinet, P., Igau, B., Nicolas, V., Notelet, L., Payrard, S., Wijnand, P., Devore, S., H. H., Li, Osho, T., Wang, L., Wei, L., Dukovic, D., Ling, Y., Benzerdjeb, H., Mednikova, Z., Trabelsi, N., Musset, M., Merrill, D., Turpault, S., Williams, B., Nortmeyer, H., Kirst, E., Witthaus, E., Chen, S., Maida, E., Auff, E., Fazekas, F., Berger, T., Bhan, V., Bouchard, J. P., Duquette, P., Freedman, M., Grand'Maison, F., Kremenchutzky, M., Bourque, C., Marrie, R. A., Melanson, M., Patry, D., Oger, J., Stefanelli, M., Jacques, F., Venegas, P., Miranda, M., Barrientos, N., Tenhamm, E., Gloger, S., Rohde, G., Mares, J., Frederiksen, J., Stenager, E., Haldre, S., Gross Paju, K., Elovaara, I., Sumelahti, M. L., Erälinna, J. P., Farkkila, M., Harno, H., Reunanen, M., Jolma, T., Camu, W., Clavelou, P., Magy, L., Debouverie, M., Edan, G., Lebrun Frenay, C., Moreau, T., Pelletier, J., Roullet, E., Alamowitch, S., Clanet, M., Hautecoeur, P., Damier, P., Rumbach, L., Chan, A., Schimrigk, S., Haas, J., Lensch, E., Diener, H., Limmroth, V., Anders, D., Berghoff, M., Oschmann, P., Stangel, M., Frese, A., Kiefer, R., Marziniak, M., Zettl, U., Stark, E., Jendroska, K., Reifschneider, G., Amato, M. P., Cosi, V., Gallo, P., Gasperini, Claudio, Ghezzi, A., Trojano, M., Pozzilli, Carlo, Montanari, E., Zwanikken, C. P., Jongen, P. J., Van Munster, E. T., Hupperts, R. M., Anten, B., Sanders, E. A., Celius, E., Hovdal, H., Krogseth, S. B., Kozubski, W., Kwiecinski, H., Czlonkowska, A., Stelmasiak, Z., Selmaj, K., Hasiec, T., Fryze, W., Drozdowski, W., Kochanowicz, J., Cunha, L., De Sa, J., Sena, A. H., Odinak, M., Skoromets, A., Gusev, E., Boiko, A., Lashch, N., Stolyarov, I., Belova, A., Malkova, N., Doronin, B., Yakupov, E., Brundin, L., Hillert, J., Karabudak, R., Irkec, C., Idiman, E., Turan, O., Efendi, H., Gedizlioglu, M., Buchakchyyska, N., Goloborodko, A., Ipatov, A., Kobets, S., Lebedynets, V., Moskovko, S., Sanotskyy, Y., Smolanka, V., Yavorskaya, V., Bates, D., Evangelou, N., Hawkins, C., Mclean, B., O'Riordan, J., Price, S., Turner, B., Barnes, D., Zajicek, J., Honeycutt, W., Khan, O., Spikol, L., Stevens, J., Klinische Neurowetenschappen, and RS: MHeNs School for Mental Health and Neuroscience
- Subjects
medicine.medical_specialty ,biology ,Nausea ,business.industry ,Incidence (epidemiology) ,Placebo-controlled study ,General Medicine ,Placebo ,Gastroenterology ,Surgery ,chemistry.chemical_compound ,Alanine transaminase ,chemistry ,Internal medicine ,Relative risk ,Teriflunomide ,medicine ,biology.protein ,medicine.symptom ,business ,Leflunomide ,medicine.drug - Abstract
Teriflunomide reduced the annualized relapse rate (0.54 for placebo vs. 0.37 for teri flunomide at either 7 or 14 mg), with relative risk reductions of 31.2% and 31.5%, respectively (P
- Published
- 2011
4. N-type bi-facial solar cells with boron emitters from doped PECVD layers
- Author
-
Frey, A., Engelhardt, J., Fritz, S., Gloger, S., Hahn, G., and Terheiden, B.
- Subjects
WAFER-BASED SILICON SOLAR CELLS AND MATERIALS TECHNOLOGY ,ddc:530 ,Silicon Solar Cell Improvements - Abstract
29th European Photovoltaic Solar Energy Conference and Exhibition; 656-660, This work is mainly focused on an alternative method for emitter formation by means of boron diffusion from a boron-doped plasma-enhanced chemical vapor deposition (PECVD) doping source. With this approach only one high temperature process is necessary for emitter and BSF/FSF formation (co-diffusion), without depletion of surface doping concentration. This enables time and cost-efficient fabrication of solar cells with high conversion efficiencies, as shown in this work, on large area (156.25 cm2) bi-facial devices with conversion efficiencies up to 19.7% measured with white back sheet. Furthermore, the contact formation with screen-printing of silver/aluminum (Ag/Al) pastes and its emitter shunting behavior due to Ag/Al spikes, varying with the firing conditions in a belt furnace, are of major interest. Low contact resistance values below 4 mΩcm2 can be realized with screen-printed Ag/Al contacts on 55-70 Ω/sq PECVD boron emitters. In addition, Ag/Al spikes with a depth of around 1-3 μm could be detected with SEM measurements.
- Published
- 2014
5. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide
- Author
-
Wolinsky, Js, Narayana, Pa, Nelson, F, Datta, S, O'Connor, P, Confavreux, C, Comi, G, Kappos, L, Olsson, Tp, Truffinet, P, Wang, L, Miller, A, Freedman MSMaida, E, Auff, E, Fazekas, F, Berger, T, Bhan, V, Bouchard, Jp, Duquette, P, Freedman, M, Grand'Maison, F, Kremenchutzky, M, Bourque, C, Marrie, Ra, Melanson, M, Patry, D, Oger, J, Stefanelli, M, Jacques, F, Venegas, P, Miranda, M, Barrientos, N, Tenhamm, E, Gloger, S, Rohde, G, Mares, J, Frederiksen, J, Stenager, E, Haldre, S, Gross Paju, K, Elovaara, I, Sumelahti, Ml, Erälinna, Jp, Färkkilä, M, Harno, H, Reunanen, M, Jolma, T, Camu, W, Clavelou, P, Magy, L, Debouverie, M, Edan, G, Lebrun Frenay, C, Moreau, T, Pelletier, J, Roullet, E, Alamowitch, S, Clanet, M, Hautecoeur, P, Damier, P, Rumbach, L, Chan, A, Schimrigk, S, Haas, J, Lensch, E, Diener, H, Limmroth, V, Anders, D, Berghoff, M, Oschmann, P, Stangel, M, Frese, A, Kiefer, R, Marziniak, M, Zettl, U, Stark, E, Jendroska, K, Reifschneider, G, Amato, Mp, Cosi, V, Gallo, Paolo, Gasperini, C, Ghezzi, A, Trojano, M, Pozzilli, C, Montanari, E, Zwanikken, Cp, Jongen, Pj, Centrum, Ms, Van Munster ET, Hupperts, Rm, Anten, B, Sanders, Ea, Celius, E, Hovdal, H, Krogseth, Sb, Kozubski, W, Kwiecinski, H, Czlonkowska, A, Stelmasiak, Z, Selmaj, K, Hasiec, T, Fryze, W, Drozdowski, W, Kochanowicz, J, Cunha, L, De Sá, J, Harrington Sena, A, Odinak, M, Skoromets, A, Gusev, E, Boiko, A, Lashch, N, Stolyarov, I, Belova, A, Malkova, N, Doronin, B, Yakupov, E, Brundin, L, Hillert, J, Karabudak, R, Irkec, C, Idiman, E, Turan, O, Efendi, H, Gedizlioglu, M, Buchakchyyska, N, Goloborodko, A, Ipatov, A, Kobets, S, Lebedynets, V, Moskovko, S, Yushchenko, Oi, Sanotskyy, Y, Smolanka, V, Yavorskaya, V, Bates, D, Evangelou, N, Hawkins, C, Mclean, B, O'Riordan, J, Price, S, Turner, B, Barnes, D, Zajicek, J, Honeycutt, W, Khan, O, Spikol, L, and Stevens, J.
- Published
- 2013
6. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- Author
-
O'Connor, P, Wolinsky, Js, Confavreux, C, Comi, G, Kappos, L, Olsson, Tp, Benzerdjeb, H, Truffinet, P, Wang, L, Miller, A, Freedman, Ms, Reingold, S, Cutter, G, Antel, J, Barkhof, F, Maddrey, W, Ravnborg, M, Schenker, S, Narayana, Pa, Nelson, F, Vainrub, I, Datta, S, He, R, Gates, B, Ton, K, Wamil, B, Igau, B, Nicolas, V, Notelet, L, Payrard, S, Wijnand, P, Devore, S, Li, Hh, Osho, T, Wei, L, Dukovic, D, Ling, Y, Mednikova, Z, Trabelsi, N, Musset, M, Merrill, D, Turpault, S, Williams, B, Nortmeyer, H, Kirst, E, Witthaus, E, Chen, S, Maida, E, Auff, E, Fazekas, F, Berger, T, Bhan, V, Bouchard, Jp, Duquette, P, Grand'Maison, F, Kremenchutzky, M, Bourque, C, Marrie, Ra, Melanson, M, Patry, D, Oger, J, Stefanelli, M, Jacques, F, Venegas, P, Miranda, M, Barrientos, N, Tenhamm, E, Gloger, S, Rohde, G, Mares, J, Frederiksen, J, Stenager, E, Haldre, S, Gross Paju, K, Elovaara, I, Sumelahti, Ml, Erälinna, Jp, Färkkilä, M, Harno, H, Reunanen, M, Jolma, T, Camu, W, Clavelou, P, Magy, L, Debouverie, M, Edan, G, Lebrun Frenay, C, Moreau, T, Pelletier, J, Roullet, E, Alamowitch, S, Clanet, M, Hautecoeur, P, Damier, P, Rumbach, L, Chan, A, Schimrigk, S, Haas, J, Lensch, E, Diener, H, Limmroth, V, Anders, D, Berghoff, M, Oschmann, P, Stangel, M, Frese, A, Kiefer, R, Marziniak, M, Zettl, U, Stark, E, Jendroska, K, Reifschneider, G, Amato, Mp, Cosi, V, Gallo, Paolo, Gasperini, C, Ghezzi, A, Trojano, M, Pozzilli, C, Montanari, E, Zwanikken, Cp, Jongen, Pj, Van Munster ET, Hupperts, Rm, Anten, B, Sanders, Ea, Celius, E, Hovdal, H, Krogseth, Sb, Kozubski, W, Kwiecinski, H, Czlonkowska, A, Stelmasiak, Z, Selmaj, K, Hasiec, T, Fryze, W, Drozdowski, W, Kochanowicz, J, Cunha, L, De Sá, J, Sena, Ah, Odinak, M, Skoromets, A, Gusev, E, Boiko, A, Lashch, N, Stolyarov, I, Belova, A, Malkova, N, Doronin, B, Yakupov, E, Brundin, L, Hillert, J, Karabudak, R, Irkec, C, Idiman, E, Turan, O, Efendi, H, Gedizlioglu, M, Buchakchyyska, N, Goloborodko, A, Ipatov, A, Kobets, S, Lebedynets, V, Moskovko, S, Sanotskyy, Y, Smolanka, V, Yavorskaya, V, Bates, D, Evangelou, N, Hawkins, C, Mclean, B, O'Riordan, J, Price, S, Turner, B, Barnes, D, Zajicek, J, Honeycutt, W, Khan, O, Spikol, L, and Stevens, J.
- Published
- 2011
7. Investigation of the back side passivation layer of screen printed bifacial silicon solar cells
- Author
-
Gloger, S., Riegel, S., Raabe, B., and Hahn, G.
- Subjects
Passivation ,Mono- and Multicrystalline Silicon Materials and Cells ,ddc:530 ,Back-surface-field ,Wafer-based Silicon Solar Cells and Materials Technology ,Bifacial - Abstract
24th European Photovoltaic Solar Energy Conference, 21-25 September 2009, Hamburg, Germany; 1544-1547, This work compares the back side passivation quality of bifacial silicon (Si) solar cells with boron back-surface-field (B-BSF) of different sheet resistances. The influence of the thickness of an additional dry thermal silicon dioxide (SiO2) to passivate the surface of the B-BSF is also investigated. The passivation quality is compared in two experiments: First Si lifetime samples with boron (B) emitter are passivated and their emitter saturation current densities (J0E) are determined with quasi-steady-state photoconductance (QSSPC) measurements after every process step. Secondly large area bifacial solar cells with different base doping are processed. The cell parameters are determined by illuminated current-voltage (IV) characteristics and the effective minority charge carrier diffusion lengths (Leff) are calculated with a model [1] using the internal quantum efficiencies (IQE) from spectral response measurements. The optimum B-BSF sheet resistance for the bifacial cell concept used is found to be 60 Ohm/sq. The optimum value of the thickness of the SiO2 layer for additional surface passivation is found to be in the range of 19- 30 nm dependent on the base doping.
- Published
- 2009
8. Treatment of spontaneous panic attacks with chlomipramine
- Author
-
Troudart T, Leon Grunhaus, Gloger S, and B Birmacher
- Subjects
Adult ,Male ,medicine.medical_specialty ,behavioral disciplines and activities ,Asymptomatic ,Pharmacological treatment ,Treatment plan ,mental disorders ,Chlomipramine ,medicine ,Humans ,Psychiatry ,Agoraphobia ,business.industry ,Panic disorder ,Panic ,Middle Aged ,medicine.disease ,Anxiety Disorders ,humanities ,Psychiatry and Mental health ,Phobic Disorders ,Clomipramine ,Female ,medicine.symptom ,business - Abstract
Recurrent spontaneous panic attacks are psychophysiological symptoms present in panic disorder and agoraphobia with panic attacks. Effective pharmacological treatment for panic attacks is essential to any treatment plan for these conditions. The authors administered chlomipramine to 20 patients who had panic disorder or agoraphobia with panic attacks, and after 8 weeks of treatment 75% of the patients with each diagnosis were asymptomatic. These results support the claim that chlomipramine is highly effective in preventing recurrence of panic attacks.
- Published
- 1981
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.